Rational Vaccines Receives UK MHRA Innovation Passport for RVx201 for the Treatment of Genital Herpes Resulting From Herpes Simplex Type 2 (HSV-2) Virus prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
25+ active players in the domain working on 25+ pipeline therapies.
Key Genital Herpes pipeline therapies such as
HSV 2 Vaccines, RVx-201, NE HSV-2 Vaccine, HDIT 101, Pritelivir, UB-621, and others are under investigation in different phases of clinical trials for the treatment of Genital Herpes.
Sanofi, Rational Vaccines, BlueWillow Biologics, Heidelberg, ImmunoTherapeutics, AiCuris, United Biopharma, among several others, are some of the key prominent pharma players working in the domain.
In
May 2021, X-Vax Technology announced that it is preparing to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its experimental vaccine against herpes simplex virus 1 and 2 (HSV-1 and -2).
Rational Vaccines Licenses Promising Technology from Louisiana State University
Vaccine candidate VC2 shows promise for herpes treatment
News provided by
Share this article
Share this article
CAMBRIDGE, Mass., April 5, 2021 /PRNewswire/ Rational Vaccines today announced a license agreement for the work of leading Louisiana State University virologist Dr. Konstantin Gus Kousoulas from LSU s School of Veterinary Medicine in the Division of Biotechnology & Molecular Medicine (BioMMED) that furthers Rational s core mission of eliminating the herpes virus. The vaccine technology, known as VC2, demonstrated great promise in the treatment of Herpes Simplex Virus 1 and 2 (HSV-1 and HSV-2) as well as facial and ocular herpes in a number of animal model studies.
Study validates pre-clinical safety of novel live-attenuated HSV-2 vaccine candidates prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
CAMBRIDGE, Mass., Feb. 26, 2021 /PRNewswire/ Leading virologist Konstantin Gus Kousoulas joined Rational Vaccines as vice president of Scientific Affairs where he will work to further the company s core mission of eradicating the world of the herpes simplex virus (HSV), the company announced today.
(PRNewsfoto/Rational Vaccines) Dr. Kousoulas is one of the world s most eminent virologists. His work in the field of HSV gives hopes to the millions of patients who are in desperate need of a better standard of care and to all of us who work to defeat this heinous virus, said Rational Vaccines CEO Agustin Fernandez. No one understands this virus better than Gus. His addition to the team brings us one step closer to our goal of eradicating the Herpes pandemic.